Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published online as doi:10.1189/jlb.1103588 on April 9, 2004

Published online before print April 9, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.1103588v1
75/6/1102    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teleshova, N.
Right arrow Articles by Pope, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teleshova, N.
Right arrow Articles by Pope, M.
(Journal of Leukocyte Biology. 2004;75:1102-1110.)
© 2004 by Society for Leukocyte Biology

Short-term Flt3L treatment effectively mobilizes functional macaque dendritic cells

Natalia Teleshova*, Jennifer Jones*,1, Jessica Kenney*, Jeanette Purcell{dagger}, Rudolf Bohm{dagger}, Agegnehu Gettie{ddagger} and Melissa Pope*,2

* Center for Biomedical Research, Population Council, New York, New York;
{dagger} Tulane National Primate Research Center, Tulane University, Covington, Louisiana; and
{ddagger} Aaron Diamond AIDS Research Center, New York, New York

2 Correspondence: Center for Biomedical Research, Population Council, 1230 York Avenue, New York, NY 10021. E-mail: mpope{at}popcbr.rockefeller.edu

In vivo administration of soluble Flt3L increases dendritic cell (DC) numbers to favor improved DC targeting of vaccine antigens, augmenting vaccine efficiency. In addition to confirming the effectiveness of human Flt3L in macaques, we strove to determine the optimal regimen to elevate numbers of functional DCs. Circulating DCs were identified within lineagehuman leukocyte antigen-DR+ cells, which comprised CD11cCD123+ plasmacytoid DCs (PDCs) and CD123 cells including CD11c+CD123 myeloid DCs as well as CD11cCD123 cells. Traditionally, DCs have been monitored 1–2 days after 10- to 14-day treatments with Flt3L (100 µg/kg/day). We demonstrate that although standard treatment increased macaque DC percentages, as little as 5–7 days of treatment was sufficient, if not more effective at mobilizing DCs. Moreover, DC frequency continued to escalate over the ensuing days, peaking at ~4 days post 7 days of treatment and ultimately decreasing thereafter. As expected, there was a more pronounced increase in the percentages and actual numbers of CD123 cells (CD11c+ and CD11c subsets) compared with PDCs. Flt3L-mobilized DCs exhibited slightly increased CD80/CD86 expression but typically still that of immature DCs and were resilient to freeze-thawing. Overnight culture activated the cells, up-regulating CD80/CD86 expression as well as interleukin-12 release, typically being boosted by CD40L. This was even more apparent for enriched DC cultures. These data verify that peak mobilization of large numbers of functional macaque DCs occurs a few days, not immediately, after short-term Flt3L dosing. This has important implications for improved DC-targeting vaccine strategies to prevent infection with human immunodeficiency virus and other pathogens.

Key Words: monkeys • PDCs • MDCs • expansion • CD80 • CD86




This article has been cited by other articles:


Home page
CVIHome page
R. K. Reeves and P. N. Fultz
Characterization of Plasmacytoid Dendritic Cells in Bone Marrow of Pig-Tailed Macaques
Clin. Vaccine Immunol., January 1, 2008; 15(1): 35 - 41.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
T. L. Papenfuss, A. P. Kithcart, N. D. Powell, M. A. McClain, I. E. Gienapp, T. M. Shawler, and C. C. Whitacre
Disease-modifying capability of murine Flt3-ligand DCs in experimental autoimmune encephalomyelitis
J. Leukoc. Biol., December 1, 2007; 82(6): 1510 - 1518.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
M. Kwissa, R. R. Amara, H. L. Robinson, B. Moss, S. Alkan, A. Jabbar, F. Villinger, and B. Pulendran
Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus
J. Exp. Med., October 29, 2007; 204(11): 2733 - 2746.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. N. Brown, A. Trichel, and S. M. Barratt-Boyes
Parallel Loss of Myeloid and Plasmacytoid Dendritic Cells from Blood and Lymphoid Tissue in Simian AIDS
J. Immunol., June 1, 2007; 178(11): 6958 - 6967.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Teleshova, J. Kenney, G. Van Nest, J. Marshall, J. D. Lifson, I. Sivin, J. Dufour, R. Bohm, A. Gettie, and M. Robbiani
Local and Systemic Effects of Intranodally Injected CpG-C Immunostimulatory-Oligodeoxyribonucleotides in Macaques
J. Immunol., December 15, 2006; 177(12): 8531 - 8541.
[Abstract] [Full Text] [PDF]


Home page
Adv. Dent. Res.Home page
N. Teleshova, J. Kenney, and M. Robbiani
Dendritic Cells and HIV Infection: Activating Dendritic Cells to Boost Immunity
Adv. Dent. Res., April 1, 2006; 19(1): 36 - 41.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. Teleshova, J. Kenney, J. Jones, J. Marshall, G. Van Nest, J. Dufour, R. Bohm, J. D. Lifson, A. Gettie, and M. Pope
CpG-C Immunostimulatory Oligodeoxyribonucleotide Activation of Plasmacytoid Dendritic Cells in Rhesus Macaques to Augment the Activation of IFN-{gamma}-Secreting Simian Immunodeficiency Virus-Specific T Cells
J. Immunol., August 1, 2004; 173(3): 1647 - 1657.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society for Leukocyte Biology.